News and Media
Publications and resources for members of the press.
News
Sumitovant Biopharma Helps Identify More Than 80 Peptide Drug Candidates for Neochromosome’s Differentiated Manufacturing Technology
NEW YORK – January 19, 2023 – Sumitovant Biopharma, Inc. (“Sumitovant”), a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company’s DrugOME™ computational platform. As part of a collaboration with Neochromosome, Inc. (“Neochromosome”), Sumitovant used extensive natural language […]
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
NEW YORK and TOKYO October 2, 2022 — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), announced today it has submitted a non-binding proposal (the “Proposal”) to the Audit Committee of the Board of Directors (the “Audit Committee”) of Myovant Sciences Ltd. (“Myovant”) offering to acquire all outstanding […]
Publications
Economic burden of congenital athymia in the United States for patients receiving supportive care during the first 3 years of life
Congenital athymia is an ultra-rare pediatric condition characterized by the lack of thymus in utero and the naïve T cells critical for infection defense and immune regulation.
ELEVATE 2: A Multicenter Study of Rodatristat Ethyl in Patients with WHO Group 1 Pulmonary Arterial Hypertension
Rodatristat ethyl is a first in class prodrug for rodatristat, a potent inhibitor of tryptophan hydroxylase, the rate limiting enzyme in the biosynthesis of serotonin from dietary tryptophan.
Defining the Clinical, Emotional, Social, and Financial Burden of Congenital Athymia
This cross-sectional study of adult caregivers of patients with congenital athymia used both a quantitative survey and qualitative interviews. Caregivers of patients currently receiving supportive care responded to questions about the past 12 months.